Kevin M. Farr Acquires 6,725 Shares of Chromadex Corp (CDXC) Stock
Chromadex Corp (NASDAQ:CDXC) insider Kevin M. Farr acquired 6,725 shares of the business’s stock in a transaction dated Thursday, March 14th. The shares were bought at an average price of $3.99 per share, with a total value of $26,832.75. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.
Shares of NASDAQ:CDXC traded down $0.18 on Thursday, reaching $3.74. 577,700 shares of the company traded hands, compared to its average volume of 187,932. Chromadex Corp has a fifty-two week low of $2.79 and a fifty-two week high of $5.11. The company has a market capitalization of $206.77 million, a PE ratio of -6.13 and a beta of 1.09. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.96 and a current ratio of 2.53.
Chromadex (NASDAQ:CDXC) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). Chromadex had a negative net margin of 105.57% and a negative return on equity of 90.20%. The company had revenue of $9.07 million for the quarter, compared to analyst estimates of $9.21 million. As a group, research analysts forecast that Chromadex Corp will post -0.34 EPS for the current fiscal year.
Several large investors have recently made changes to their positions in CDXC. Northern Trust Corp lifted its position in shares of Chromadex by 113.4% during the 2nd quarter. Northern Trust Corp now owns 119,300 shares of the company’s stock valued at $443,000 after acquiring an additional 63,398 shares during the last quarter. Tieton Capital Management LLC lifted its position in shares of Chromadex by 19.0% during the 3rd quarter. Tieton Capital Management LLC now owns 1,081,245 shares of the company’s stock valued at $4,639,000 after acquiring an additional 172,394 shares during the last quarter. BlackRock Inc. lifted its position in shares of Chromadex by 1.5% during the 3rd quarter. BlackRock Inc. now owns 1,913,433 shares of the company’s stock valued at $8,209,000 after acquiring an additional 28,817 shares during the last quarter. Citadel Advisors LLC lifted its position in shares of Chromadex by 160.5% during the 3rd quarter. Citadel Advisors LLC now owns 44,336 shares of the company’s stock valued at $190,000 after acquiring an additional 27,315 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Chromadex by 5.9% in the third quarter. Vanguard Group Inc. now owns 1,572,078 shares of the company’s stock valued at $6,744,000 after purchasing an additional 88,125 shares in the last quarter. Institutional investors own 17.30% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Kevin M. Farr Acquires 6,725 Shares of Chromadex Corp (CDXC) Stock” was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.watchlistnews.com/kevin-m-farr-acquires-6725-shares-of-chromadex-corp-cdxc-stock/2890642.html.
Chromadex Company Profile
ChromaDex Corporation operates as a nutraceutical company. The company offers research and quality control products and services to dietary supplements, food, beverages, cosmetic, and pharmaceutical industries; Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide(NAD) level used for healthy aging; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients.
Further Reading: What impact do institutional investors have on markets?
Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.